Lexicon Pharmaceuticals’ (LXRX) “Buy” Rating Reaffirmed at HC Wainwright

Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $4.00 price target on the biopharmaceutical company’s stock.

Separately, Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, January 29th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Lexicon Pharmaceuticals has an average rating of “Hold” and a consensus target price of $5.00.

Lexicon Pharmaceuticals Stock Down 49.8 %

NASDAQ LXRX traded down $0.35 during mid-day trading on Monday, reaching $0.35. The stock had a trading volume of 44,168,289 shares, compared to its average volume of 5,609,503. The company has a fifty day moving average price of $0.77 and a 200 day moving average price of $1.18. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. Lexicon Pharmaceuticals has a 1 year low of $0.35 and a 1 year high of $2.83. The stock has a market cap of $86.43 million, a PE ratio of -0.47 and a beta of 1.04.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its holdings in Lexicon Pharmaceuticals by 71.2% during the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 13,246 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Lexicon Pharmaceuticals by 2.1% in the 4th quarter. Wellington Management Group LLP now owns 747,996 shares of the biopharmaceutical company’s stock worth $552,000 after buying an additional 15,249 shares during the period. Arizona State Retirement System increased its stake in Lexicon Pharmaceuticals by 34.4% in the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 16,136 shares in the last quarter. Teacher Retirement System of Texas raised its holdings in Lexicon Pharmaceuticals by 60.3% during the fourth quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 24,615 shares during the period. Finally, Bank of America Corp DE lifted its position in shares of Lexicon Pharmaceuticals by 27.4% in the fourth quarter. Bank of America Corp DE now owns 136,407 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 29,319 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.